{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:51:21Z","timestamp":1723683081512},"reference-count":4,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/2327-6924.12330","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T15:13:48Z","timestamp":1450365228000},"page":"721-731","source":"Crossref","is-referenced-by-count":2,"title":["Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism"],"prefix":"10.1097","volume":"27","author":[{"given":"Barbara A.","family":"Bentz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"3","key":"R6-11-20210915","first-page":"139","article-title":"Adherence and dosing frequency of common medications for cardiovascular patients.","volume":"18","author":"Bae","year":"2012","journal-title":"American Journal of Managed Care"},{"issue":"9","key":"R9-11-20210915","doi-asserted-by":"crossref","first-page":"789","DOI":"10.18553\/jmcp.2013.19.9.789","article-title":"Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.","volume":"19","author":"Biskupiak","year":"2013","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"Suppl 1","key":"R34-11-20210915","first-page":"23","article-title":"Switching from dabigatran or rivaroxaban to edoxaban: A biomarker assessment in healthy subjects.","volume":"12","author":"Parasrampuria","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"RU35-11-20210915","first-page":"S83","article-title":"Pharmacokinetics of edoxaban, a novel oral anticoagulant, when dosed alone or following switching from dabigatran or rivaroxaban.","volume":"95","author":"Parasrampuria","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12330","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01741002-201512000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:22:36Z","timestamp":1631712156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201512000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":4,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12330","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}